The European Network for Gynaecological Oncological Trial groups (ENGOT) is a research network of the European Society of Gynaecological Oncology (ESGO) and was founded in Berlin in October 2007.
Currently, ENGOT consists of 19 trial groups from 15 European countries that perform cooperative clinical trials. View the on-going clinical trials.
ENGOT's ultimate goal is to bring the best treatment to gynecological cancer patients through the best science, and enabling every patient in every European country to access a clinical trial.
ENGOT is a platform that guarantees that the European spirit and culture is incorporated into the medical progress in gynaecological oncology, and that all European patients and countries can participate in an active way in clinical research and progress.
The ultimate goal is to bring the best treatment to gynecological cancer patients through the best science, and enabling every patient in every European country to access a clinical trial.
To download ENGOT bylaws, click here.
As a network of national and regional clinical trial units, ENGOT coordinates and promotes clinical trials within Europe on patients with gynaecological cancer.
This coordination is particularly relevant for academic clinical trials, translational research, research on rare diseases, and for clinical trials sponsored by the industry to perform multinational studies in Europe.
The ENGOT Assembly further set up the following objectives and strategies:
ENGOT runs the Gynaecological Cancer Academy (GCA), an educative programme aiming to nurture and develop the next generation of leaders in gynaecological oncology to ensure continuity and transfer of knowledge and experience within the clinical trial community.
The GCA training modules and Clinical Trials´ Expert Platform comprise of two 1.5 – 2-day workshops delivered twice a year in different countries within the ENGOT region.
In addition, the recent GCA workshops the GCA were combined with topics covering the translational research, Phase 1/Phase 2 trials and Ph1 drugs development whilst researchers and specialist in Ph1-2 clinical studies were involved.
The most important presentations of these training modules from all of the GCA events were webcasted and are now available on ESGO eAcademy.
View over 40 selected webcasts from the GCA workshops.
ENGOT Clinical Trials Brochure
ENGOT´s Requirements from trials Trials Between Academic Groups and Pharmaceutical Companies
(Int J of Gynecological Cancer: 2010, 20: pp 476-478)
ENGOT's Requirements for Trials Between Academic Groups and Industry Partners - First Update 2015
(Int J Gynecol Cancer: 2015 Sep; 25(7):1328-30. doi: 10.1097/IGC.0000000000000478)
Roadmap for the ENGOT trials
(Int J of Gynecological Cancer: 2013, 23: pp 1339-1343)
ENGOT guidelines for authorship
Guidelines for ENGOT minimal requirements for site selection
ENGOT Privileged Partnership
(Int J Gynecol Cancer 2015; 25: 00-00)
For more information about ENGOT, please contact:
ENGOT Administrative Office, E-mail: firstname.lastname@example.org
For medical questions, please contact:
Prof. Sandro Pignata
Uro-Gynecological Department, Division of Medical Oncology
IRCCS National Cancer Institute “Fondazione G. Pascale”
For administrative questions on trials, please contact:
Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie
Support ESGO educational activities and help us develop more opportunities for colleagues from low resource areas.
Get notified on all news and activities right in your mailbox.
The European Society of Gynaecological Oncology (ESGO) is the leading European organisation with more than 2,500 professionals involved in treatment, care and research of gynaecologic cancers.
Get notified on all of ESGO’s news and activities.
European Society of Gyneacological Oncology (ESGO)
rue François-Versonnex 7, P.O.BOX 6053